AU2010261967B2 - New therapeutical uses of inecalcitol - Google Patents

New therapeutical uses of inecalcitol Download PDF

Info

Publication number
AU2010261967B2
AU2010261967B2 AU2010261967A AU2010261967A AU2010261967B2 AU 2010261967 B2 AU2010261967 B2 AU 2010261967B2 AU 2010261967 A AU2010261967 A AU 2010261967A AU 2010261967 A AU2010261967 A AU 2010261967A AU 2010261967 B2 AU2010261967 B2 AU 2010261967B2
Authority
AU
Australia
Prior art keywords
inecalcitol
day
use according
anyone
administration
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2010261967A
Other languages
English (en)
Other versions
AU2010261967A1 (en
Inventor
Remi Delansorne
Jean-Francois Dufour-Lamartinie
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Aton SA
Original Assignee
Hybrigenics SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hybrigenics SA filed Critical Hybrigenics SA
Publication of AU2010261967A1 publication Critical patent/AU2010261967A1/en
Application granted granted Critical
Publication of AU2010261967B2 publication Critical patent/AU2010261967B2/en
Ceased legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/59—Compounds containing 9, 10- seco- cyclopenta[a]hydrophenanthrene ring systems
    • A61K31/593—9,10-Secocholestane derivatives, e.g. cholecalciferol, i.e. vitamin D3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/18—Drugs for disorders of the endocrine system of the parathyroid hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/18—Drugs for disorders of the endocrine system of the parathyroid hormones
    • A61P5/20—Drugs for disorders of the endocrine system of the parathyroid hormones for decreasing, blocking or antagonising the activity of PTH
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Immunology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Obesity (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Emergency Medicine (AREA)
  • Nutrition Science (AREA)
  • Urology & Nephrology (AREA)
  • Dermatology (AREA)
  • Oncology (AREA)
  • Reproductive Health (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Physiology (AREA)
  • Transplantation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
AU2010261967A 2009-05-20 2010-05-18 New therapeutical uses of inecalcitol Ceased AU2010261967B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US17990609P 2009-05-20 2009-05-20
US61/179,906 2009-05-20
PCT/EP2010/056832 WO2010145903A1 (en) 2009-05-20 2010-05-18 New therapeutical uses of inecalcitol

Publications (2)

Publication Number Publication Date
AU2010261967A1 AU2010261967A1 (en) 2011-12-08
AU2010261967B2 true AU2010261967B2 (en) 2016-03-03

Family

ID=42308305

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2010261967A Ceased AU2010261967B2 (en) 2009-05-20 2010-05-18 New therapeutical uses of inecalcitol

Country Status (23)

Country Link
US (1) US8481514B2 (cg-RX-API-DMAC10.html)
EP (1) EP2263677B1 (cg-RX-API-DMAC10.html)
JP (2) JP2012527424A (cg-RX-API-DMAC10.html)
KR (1) KR101845320B1 (cg-RX-API-DMAC10.html)
CN (1) CN102448466A (cg-RX-API-DMAC10.html)
AT (1) ATE505194T1 (cg-RX-API-DMAC10.html)
AU (1) AU2010261967B2 (cg-RX-API-DMAC10.html)
BR (1) BRPI1009056A2 (cg-RX-API-DMAC10.html)
CA (1) CA2762458C (cg-RX-API-DMAC10.html)
DE (1) DE602010000019D1 (cg-RX-API-DMAC10.html)
DK (1) DK2263677T3 (cg-RX-API-DMAC10.html)
ES (1) ES2363070T3 (cg-RX-API-DMAC10.html)
HR (1) HRP20110433T1 (cg-RX-API-DMAC10.html)
IL (1) IL216418A (cg-RX-API-DMAC10.html)
MX (1) MX2011012330A (cg-RX-API-DMAC10.html)
NZ (1) NZ596497A (cg-RX-API-DMAC10.html)
PL (1) PL2263677T3 (cg-RX-API-DMAC10.html)
PT (1) PT2263677E (cg-RX-API-DMAC10.html)
RU (1) RU2571490C2 (cg-RX-API-DMAC10.html)
SG (1) SG176581A1 (cg-RX-API-DMAC10.html)
SI (1) SI2263677T1 (cg-RX-API-DMAC10.html)
UA (1) UA105792C2 (cg-RX-API-DMAC10.html)
WO (1) WO2010145903A1 (cg-RX-API-DMAC10.html)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK2360145T3 (da) 2010-01-26 2012-07-09 Hybrigenics Sa Hidtil ukendt fremgangsmåde til isomerisering af kondenserede bicykliske strukturer og fremstilling af D-vitaminanaloger, der omfatter disse
EP2407152A1 (en) * 2010-07-15 2012-01-18 Hybrigenics S.A. Formulations of 14-epi-analogues of vitamin D
AU2011278346B2 (en) * 2010-07-15 2016-04-07 Hybrigenics Sa New formulations of 14 - epi -analogues of vitamin D
US20120015913A1 (en) 2010-07-15 2012-01-19 Delansorne Remi Formulations of 14-EPI-Analogues of Vitamin D
WO2015193480A1 (en) * 2014-06-19 2015-12-23 INSERM (Institut National de la Santé et de la Recherche Médicale) Composition comprising a combination of dna methylation inhibitor and a vitamin d receptor agonist for the treatment of drug resistant cancer or for the prevention of tumor relapse
SG11201809501PA (en) 2016-06-06 2018-12-28 Celgene Corp Treatment of a hematologic malignancy with 2-(4-chlorophenyl)-n-((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl)methyl)-2,2-difluoroacetamide
JP2020143008A (ja) * 2019-03-05 2020-09-10 達也 楠堂 新規褐色脂肪細胞分化誘導剤

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0972762A2 (en) * 1993-07-09 2000-01-19 Laboratoire Theramex Novel structural analogues of vitamin D

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6242434B1 (en) * 1997-08-08 2001-06-05 Bone Care International, Inc. 24-hydroxyvitamin D, analogs and uses thereof
GB0305332D0 (en) * 2003-03-10 2003-04-09 Leuven K U Res & Dev Biological evaluation of novel vitamin D analogues
CA2580962A1 (en) * 2004-09-24 2006-04-06 Bioxell S.P.A. 20-cycloalkyl,26,27-alkyl/haloalkyl vitamin d3 compounds and methods of use thereof

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0972762A2 (en) * 1993-07-09 2000-01-19 Laboratoire Theramex Novel structural analogues of vitamin D

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
EELEN, G. et al., "Superagonistic Action of 14-epi-Analogs of 1,25-Dihydroxyvitamin D Explained by Vitamin D Receptor-Coactivator Interaction", Molecular Pharmacology, 2005, Vol. 67, Page 1566-1573. *
EELEN, G. et al., "Vitamin D Analogs and Coactivators", Anticancer Research, 2006, Vol. 26, Page 2717-2722. *
Hybrigenics: "Promising Interim Results from Hybrigenics' lnecalcitol Phase II in Combination with Taxotere(R) for Hormone-Refractory Prostate Cancer", 19 April 2009, URL: http://www.medicalnewstoday.com/releases/146552.php, viewed 17/09/15 *
VERLINDEN, L. et al., "Two Novel 14-Epi-Analogues of 1,25-Dihydroxyvitamin D3 Inhibit the Growth of Human Breast Cancer Cells in Vitro and in Vivo", Cancer Research, 2000, Vol. 60, Page 2673-2679. *

Also Published As

Publication number Publication date
IL216418A0 (en) 2012-02-29
SI2263677T1 (sl) 2011-07-29
UA105792C2 (uk) 2014-06-25
EP2263677B1 (en) 2011-04-13
RU2011151854A (ru) 2013-06-27
RU2571490C2 (ru) 2015-12-20
JP2016179994A (ja) 2016-10-13
KR20120017075A (ko) 2012-02-27
EP2263677A1 (en) 2010-12-22
SG176581A1 (en) 2012-01-30
PL2263677T3 (pl) 2011-09-30
CN102448466A (zh) 2012-05-09
US20110015276A1 (en) 2011-01-20
DE602010000019D1 (de) 2011-05-26
JP2012527424A (ja) 2012-11-08
ES2363070T3 (es) 2011-07-19
WO2010145903A1 (en) 2010-12-23
MX2011012330A (es) 2011-12-16
ATE505194T1 (de) 2011-04-15
AU2010261967A1 (en) 2011-12-08
DK2263677T3 (da) 2011-06-06
CA2762458A1 (en) 2010-12-23
HRP20110433T1 (hr) 2011-07-31
US8481514B2 (en) 2013-07-09
NZ596497A (en) 2013-05-31
KR101845320B1 (ko) 2018-04-04
PT2263677E (pt) 2011-06-01
BRPI1009056A2 (pt) 2020-06-02
CA2762458C (en) 2018-08-28
IL216418A (en) 2015-09-24

Similar Documents

Publication Publication Date Title
EP0948334B1 (en) Method of treating prostatic diseases using active vitamin d analogues
EP2340840B1 (en) Pulse dose Vitamin D drug for the treatment of hyperproliferative skin diseases
EP0951286B1 (en) Method of treating prostatic diseases using delayed and/or sustained release vitamin d formulations
CA2762458C (en) New therapeutical uses of inecalcitol
JP2005510536A (ja) 活性ビタミンｄ類縁物質を使用した過剰増殖性疾病の治療
US20080233206A1 (en) Compositions and methods for anti-inflammatory treatments
JPH07501343A (ja) 経口用１α−ヒドロキシプレビタミンＤ
US7094775B2 (en) Method of treating breast cancer using a combination of vitamin D analogues and other agents
AU2004220622A1 (en) Method of treating and preventing hyperparathyroidism with vitamin D2 or D4 compounds
JP2011140521A (ja) タキサンにより惹起される神経毒性を予防又は軽減するための薬剤
US11026906B2 (en) Pharmaceutical quality strontium L-lactate
JP4672257B2 (ja) エポチロンを含む組成物およびカルチノイド症候群の治療のためのそれらの使用
CN110636847B (zh) 用于预防及治疗肌肉疾病的组合物
ES2398640T3 (es) Formulaciones de análogos 14-epi de la vitamina D
CN100386083C (zh) 用维生素d类化合物制备治疗骨髓发育不良综合症药物的方法
EP1553938A1 (en) Use of epothilone derivatives for the treatment of hyperparathyroidism
AU2012230089B2 (en) Anti-inflammatory compositions comprising tetracyclines and use thereof in therapy
JPH11116501A (ja) 骨吸収関連疾患治療剤

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired